Diagnostic potential for a serum miRNA neural network for detection of ovarian cancer

eLife

Volumn 6, Issue , 2017, Pages

  Elias, Kevin M ^a,b,c   Fendler, Wojciech ^a,b,d   Stawiski, Konrad ^d   Fiascone, Stephen J ^a,b   Vitonis, Allison F ^b,c,e   Berkowitz, Ross S ^a,b   Frendl, Gyorgy ^b,c   Konstantinopoulos, Panagiotis ^a,b   Crum, Christopher P ^b,c   Kedzierska, Magdalena ^d   Cramer, Daniel W ^b,c,e   Chowdhury, Dipanjan ^a,b  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d MEDICAL UNIVERSITY OF LODZ   (Poland)

^e HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CA 125 ANTIGEN; KI 67 ANTIGEN; MICRORNA; PROTEIN P53; TUMOR MARKER;

ADULT; ARTICLE; ARTIFICIAL NEURAL NETWORK; BAYES THEOREM; CANCER DIAGNOSIS; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DISCRIMINANT ANALYSIS; FEMALE; FLOW CYTOMETRY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; MAJOR CLINICAL STUDY; MIDDLE AGED; NEXT GENERATION SEQUENCING; OVARY CARCINOMA; PREDICTIVE VALUE; RANDOM FOREST; REAL TIME POLYMERASE CHAIN REACTION; RNA SEQUENCE; SENSITIVITY AND SPECIFICITY; SUPPORT VECTOR MACHINE; AGED; BLOOD; CHEMISTRY; OVARY TUMOR; PATHOLOGY; SERUM; VALIDATION STUDY;

AGED; BIOMARKERS, TUMOR; FEMALE; HUMANS; MICRORNAS; MIDDLE AGED; NEURAL NETWORKS (COMPUTER); OVARIAN NEOPLASMS; PREDICTIVE VALUE OF TESTS; REAL-TIME POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY; SERUM;

EID: 85036524079     PISSN: None     EISSN: 2050084X     Source Type: Journal    
DOI: 10.7554/eLife.28932     Document Type: Article

References (56)

1. Alhasan AH, Scott AW, Wu JJ, Feng G, Meeks JJ, Thaxton CS, Mirkin CA. 2016. Circulating microRNA signature for the diagnosis of very high-risk prostate cancer. PNAS 113:10655-10660. DOI:https://doi.org/10.1073/pnas.1611596113
2. Andersen CL, Jensen JL, Ørntoft TF. 2004. Normalization of real-time quantitative reverse transcription-PCR data: a model-based variance estimation approach to identify genes suited for normalization, applied to bladder and colon cancer data sets. Cancer Research 64:5245-5250. DOI:https://doi.org/10.1158/0008-5472.CAN-04-0496
3. Bagnoli M, Canevari S, Califano D, Losito S, Maio MD, Raspagliesi F, Carcangiu ML, Toffoli G, Cecchin E, Sorio R, Canzonieri V, Russo D, Scognamiglio G, Chiappetta G, Baldassarre G, Lorusso D, Scambia G, Zannoni GF, Savarese A, Carosi M, et al. 2016. Development and validation of a microRNA-based signature (MiROvaR) to predict early relapse or progression of epithelial ovarian cancer: a cohort study. The Lancet Oncology 17:1137-1146. DOI:https://doi.org/10.1016/S1470-2045(16)30108-5
4. Broyden CG. 1970. The convergence of a class of double-rank minimization algorithms 1. general considerations. IMA Journal of Applied Mathematics 6:76-90. DOI:https://doi.org/10.1093/imamat/6.1.76
5. Bustin SA, Benes V, Garson JA, Hellemans J, Huggett J, Kubista M, Mueller R, Nolan T, Pfaffl MW, Shipley GL, Vandesompele J, Wittwer CT. 2009. The MIQE guidelines: minimum information for publication of quantitative real-time PCR experiments. Clinical Chemistry 55:611-622. DOI:https://doi.org/10.1373/clinchem.2008.112797
6. Chung YW, Bae HS, Song JY, Lee JK, Lee NW, Kim T, Lee KW. 2013. Detection of microRNA as novel biomarkers of epithelial ovarian cancer from the serum of ovarian cancer patients. International Journal of Gynecological Cancer 23:673-679. DOI:https://doi.org/10.1097/IGC.0b013e31828c166d
7. Coleman RL, Herzog TJ, Chan DW, Munroe DG, Pappas TC, Smith A, Zhang Z, Wolf J. 2016. Validation of a second-generation multivariate index assay for malignancy risk of adnexal masses. American Journal of Obstetrics and Gynecology 215:82.e1-8282. DOI:https://doi.org/10.1016/j.ajog.2016.03.003
8. Collins GS, Reitsma JB, Altman DG, Moons KG. 2015. Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD): the TRIPOD statement. Annals of Internal Medicine 162:55-63. DOI:https://doi.org/10.7326/M14-0697
9. Cramer DW, Vitonis AF, Welch WR, Terry KL, Goodman A, Rueda BR, Berkowitz RS. 2010. Correlates of the preoperative level of CA125 at presentation of ovarian cancer. Gynecologic Oncology 119:462-468. DOI:https://doi.org/10.1016/j.ygyno.2010.08.028
10. Cramer DW, Elias KM. 2016. A prognostically relevant miRNA signature for epithelial ovarian cancer. The Lancet Oncology 17:1032-1033. DOI:https://doi.org/10.1016/S1470-2045(16)30149-8
11. Deb B, Uddin A, Chakraborty S. 2017. miRNAs and ovarian cancer: An overview. Journal of Cellular Physiology. DOI:https://doi.org/10.1002/jcp.26095
12. Dinh TK, Fendler W, Chałubińska-Fendler J, Acharya SS, O’Leary C, Deraska PV, D’Andrea AD, Chowdhury D, Kozono D. 2016. Circulating miR-29a and miR-150 correlate with delivered dose during thoracic radiation therapy for non-small cell lung cancer. Radiation Oncology 11:61. DOI:https://doi.org/10.1186/s13014-016-0636-4
13. Earle CC, Schrag D, Neville BA, Yabroff KR, Topor M, Fahey A, Trimble EL, Bodurka DC, Bristow RE, Carney M, Warren JL. 2006. Effect of surgeon specialty on processes of care and outcomes for ovarian cancer patients. JNCI: Journal of the National Cancer Institute 98:172-180. DOI:https://doi.org/10.1093/jnci/djj019
14. Elias KM, Fusco A, Kang S, Michaud D, Berkowitz RS, Horowitz NS, Frendl G. 2015. A prospective phase 0 study on the effects of anesthetic selection on serum miRNA profiles during primary cytoreductive surgery for suspected ovarian cancer. Gynecologic Oncology 137:1. DOI:https://doi.org/10.1016/j.ygyno.2015.01.341
15. Fletcher R. 1970. A new approach to variable metric algorithms. The Computer Journal 13:317-322. DOI:https://doi.org/10.1093/comjnl/13.3.317
16. Goldfarb D. 1970. A family of variable-metric methods derived by variational means. Mathematics of Computation 24:23-26. DOI:https://doi.org/10.1090/S0025-5718-1970-0258249-6
17. Hall MA. 1998. Correlation-Based Feature Subset Selection for Machine Learning. Hamilton, New Zealand: University of Waikato.
18. Hanley JA, McNeil BJ. 1982. The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology 143:29-36. DOI:https://doi.org/10.1148/radiology.143.1.7063747
19. Häusler SF, Keller A, Chandran PA, Ziegler K, Zipp K, Heuer S, Krockenberger M, Engel JB, Hönig A, Scheffler M, Dietl J, Wischhusen J. 2010. Whole blood-derived miRNA profiles as potential new tools for ovarian cancer screening. British Journal of Cancer 103:693-700. DOI:https://doi.org/10.1038/sj.bjc.6605833
20. Jacobs IJ, Menon U, Ryan A, Gentry-Maharaj A, Burnell M, Kalsi JK, Amso NN, Apostolidou S, Benjamin E, Cruickshank D, Crump DN, Davies SK, Dawnay A, Dobbs S, Fletcher G, Ford J, Godfrey K, Gunu R, Habib M, Hallett R, et al. 2016. Ovarian cancer screening and mortality in the UK collaborative trial of ovarian cancer screening (UKCTOCS): a randomised controlled trial. The Lancet 387:945-956. DOI:https://doi.org/10.1016/S0140-6736(15)01224-6
21. Johnson WE, Li C, Rabinovic A. 2007. Adjusting batch effects in microarray expression data using empirical Bayes methods. Biostatistics 8:118-127. DOI:https://doi.org/10.1093/biostatistics/kxj037
22. Karst AM, Drapkin R. 2010. Ovarian cancer pathogenesis: a model in evolution. Journal of Oncology 2010: 932371-13. DOI:https://doi.org/10.1155/2010/932371
23. Katz B, Tropé CG, Reich R, Davidson B. 2015. MicroRNAs in ovarian cancer. Human Pathology 46:1245-1256. DOI:https://doi.org/10.1016/j.humpath.2015.06.013
24. Keller A, Leidinger P, Bauer A, Elsharawy A, Haas J, Backes C, Wendschlag A, Giese N, Tjaden C, Ott K, Werner J, Hackert T, Ruprecht K, Huwer H, Huebers J, Jacobs G, Rosenstiel P, Dommisch H, Schaefer A, Müller-Quernheim J, et al. 2011. Toward the blood-borne miRNome of human diseases. Nature Methods 8:841-843. DOI:https://doi.org/10.1038/nmeth.1682
25. Langhe R, Norris L, Saadeh FA, Blackshields G, Varley R, Harrison A, Gleeson N, Spillane C, Martin C, O’Donnell DM, D’Arcy T, O’Leary J, O’Toole S. 2015. A novel serum microRNA panel to discriminate benign from malignant ovarian disease. Cancer Letters 356:628-636. DOI:https://doi.org/10.1016/j.canlet.2014.10.010
26. Li P, Teng F, Gao F, Zhang M, Wu J, Zhang C. 2015. Identification of circulating microRNAs as potential biomarkers for detecting acute ischemic stroke. Cellular and Molecular Neurobiology 35:433-447. DOI:https://doi.org/10.1007/s10571-014-0139-5
27. Merritt WM, Lin YG, Han LY, Kamat AA, Spannuth WA, Schmandt R, Urbauer D, Pennacchio LA, Cheng JF, Nick AM, Deavers MT, Mourad-Zeidan A, Wang H, Mueller P, Lenburg ME, Gray JW, Mok S, Birrer MJ, Lopez-Berestein G, Coleman RL, et al. 2008. Dicer, Drosha, and outcomes in patients with ovarian cancer. New England Journal of Medicine 359:2641-2650. DOI:https://doi.org/10.1056/NEJMoa0803785
28. Mestdagh P, Hartmann N, Baeriswyl L, Andreasen D, Bernard N, Chen C, Cheo D, D’Andrade P, DeMayo M, Dennis L, Derveaux S, Feng Y, Fulmer-Smentek S, Gerstmayer B, Gouffon J, Grimley C, Lader E, Lee KY, Luo S, Mouritzen P, et al. 2014. Evaluation of quantitative miRNA expression platforms in the microRNA quality control (miRQC) study. Nature Methods 11:809-815. DOI:https://doi.org/10.1038/nmeth.3014
29. Moore RG, Jabre-Raughley M, Brown AK, Robison KM, Miller MC, Allard WJ, Kurman RJ, Bast RC, Skates SJ. 2010. Comparison of a novel multiple marker assay vs the Risk of Malignancy Index for the prediction of epithelial ovarian cancer in patients with a pelvic mass. American Journal of Obstetrics and Gynecology 203: 228.e1-22228. DOI:https://doi.org/10.1016/j.ajog.2010.03.043
30. Moss EL, Hollingworth J, Reynolds TM. 2005. The role of CA125 in clinical practice. Journal of Clinical Pathology 58:308-312. DOI:https://doi.org/10.1136/jcp.2004.018077
31. Nakamura K, Sawada K, Yoshimura A, Kinose Y, Nakatsuka E, Kimura T. 2016. Clinical relevance of circulating cell-free microRNAs in ovarian cancer. Molecular Cancer 15:48. DOI:https://doi.org/10.1186/s12943-016-0536-0
32. Pecot CV, Rupaimoole R, Yang D, Akbani R, Ivan C, Lu C, Wu S, Han HD, Shah MY, Rodriguez-Aguayo C, Bottsford-Miller J, Liu Y, Kim SB, Unruh A, Gonzalez-Villasana V, Huang L, Zand B, Moreno-Smith M, Mangala LS, Taylor M, et al. 2013. Tumour angiogenesis regulation by the miR-200 family. Nature Communications 4: 2427. DOI:https://doi.org/10.1038/ncomms3427
33. Perets R, Wyant GA, Muto KW, Bijron JG, Poole BB, Chin KT, Chen JY, Ohman AW, Stepule CD, Kwak S, Karst AM, Hirsch MS, Setlur SR, Crum CP, Dinulescu DM, Drapkin R. 2013. Transformation of the fallopian tube secretory epithelium leads to high-grade serous ovarian cancer in Brca;Tp53;Pten models. Cancer Cell 24:751-765. DOI:https://doi.org/10.1016/j.ccr.2013.10.013
34. Resnick KE, Alder H, Hagan JP, Richardson DL, Croce CM, Cohn DE. 2009. The detection of differentially expressed microRNAs from the serum of ovarian cancer patients using a novel real-time PCR platform. Gynecologic Oncology 112:55-59. DOI:https://doi.org/10.1016/j.ygyno.2008.08.036
35. Rice MS, Murphy MA, Vitonis AF, Cramer DW, Titus LJ, Tworoger SS, Terry KL. 2013. Tubal ligation, hysterectomy and epithelial ovarian cancer in the New England Case-Control Study. International Journal of Cancer 133:2415-2421. DOI:https://doi.org/10.1002/ijc.28249
36. Samuel P, Carter DR. 2016. The diagnostic and prognostic potential of micrornas in epithelial ovarian carcinoma. Molecular Diagnosis & Therapy 21:59-73. DOI:https://doi.org/10.1007/s40291-016-0242-z
37. Schorge JO, Modesitt SC, Coleman RL, Cohn DE, Kauff ND, Duska LR, Herzog TJ. 2010. SGO white paper on ovarian cancer: etiology, screening and surveillance. Gynecologic Oncology 119:7-17. DOI:https://doi.org/10.1016/j.ygyno.2010.06.003
38. Shanno DF. 1970. Conditioning of quasi-Newton methods for function minimization. Mathematics of Computation 24:647-656. DOI:https://doi.org/10.1090/S0025-5718-1970-0274029-X
39. Shanno DF, Kettler PC. 1970. Optimal conditioning of quasi-Newton methods. Mathematics of Computation 24: 657-664. DOI:https://doi.org/10.1090/S0025-5718-1970-0274030-6
40. Siegel RL, Miller KD, Jemal A. 2016. Cancer statistics, 2016. CA: A Cancer Journal for Clinicians 66:7-30. DOI:https://doi.org/10.3322/caac.21332
41. Skates SJ, Jacobs IJ, Knapp RC. 2001. Tumor markers in screening for ovarian cancer. Methods in Molecular Medicine 39:61-73. DOI:https://doi.org/10.1385/1-59259-071-3:61
42. Terry KL, Schock H, Fortner RT, Hüsing A, Fichorova RN, Yamamoto HS, Vitonis AF, Johnson T, Overvad K, Tjønneland A, Boutron-Ruault MC, Mesrine S, Severi G, Dossus L, Rinaldi S, Boeing H, Benetou V, Lagiou P, Trichopoulou A, Krogh V, et al. 2016. A prospective evaluation of early detection biomarkers for ovarian cancer in the european EPIC cohort. Clinical Cancer Research 22:4664-4675. DOI:https://doi.org/10.1158/1078-0432.CCR-16-0316
43. Todeschini P, Salviato E, Paracchini L, Ferracin M, Petrillo M, Zanotti L, Tognon G, Gambino A, Calura E, Caratti G, Martini P, Beltrame L, Maragoni L, Gallo D, Odicino FE, Sartori E, Scambia G, Negrini M, Ravaggi A, D’Incalci M, et al. 2017. Circulating miRNA landscape identifies miR-1246 as promising diagnostic biomarker in high-grade serous ovarian carcinoma: A validation across two independent cohorts. Cancer Letters 388:320-327. DOI:https://doi.org/10.1016/j.canlet.2016.12.017
44. Ueland FR, Desimone CP, Seamon LG, Miller RA, Goodrich S, Podzielinski I, Sokoll L, Smith A, van Nagell JR, Zhang Z. 2011. Effectiveness of a multivariate index assay in the preoperative assessment of ovarian tumors. Obstetrics & Gynecology 117:1289-1297. DOI:https://doi.org/10.1097/AOG.0b013e31821b5118
45. Vandesompele J, De Preter K, Pattyn F, Poppe B, Van Roy N, De Paepe A, Speleman F. 2002. Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biology 3:RESEARCH0034.
46. Vorwerk S, Ganter K, Cheng Y, Hoheisel J, Stähler PF, Beier M. 2008. Microfluidic-based enzymatic on-chip labeling of miRNAs. New Biotechnology 25:142-149. DOI:https://doi.org/10.1016/j.nbt.2008.08.005
47. Wang Y, Sundfeldt K, Mateoiu C, Shih I, Kurman RJ, Schaefer J, Silliman N, Kinde I, Springer S, Foote M, Kristjansdottir B, James N, Kinzler KW, Papadopoulos N, Diaz LA, Vogelstein B. 2016. Diagnostic potential of tumor DNA from ovarian cyst fluid. eLife 5:e15175. DOI:https://doi.org/10.7554/eLife.15175
48. Williams KA, Labidi-Galy SI, Terry KL, Vitonis AF, Welch WR, Goodman A, Cramer DW. 2014. Prognostic significance and predictors of the neutrophil-to-lymphocyte ratio in ovarian cancer. Gynecologic Oncology 132: 542-550. DOI:https://doi.org/10.1016/j.ygyno.2014.01.026
49. Witten I. 2016. Data Mining: Practical Machine Learning Tools and Techniques. Boston, MA: Elsevier.
50. Wu Y, Wei B, Liu H, Li T, Rayner S. 2011. MiRPara: a SVM-based software tool for prediction of most probable microRNA coding regions in genome scale sequences. BMC Bioinformatics 12:107. DOI:https://doi.org/10.1186/1471-2105-12-107
51. Youden WJ. 1950. Index for rating diagnostic tests. Cancer 3:32-35. DOI:https://doi.org/10.1002/1097-0142(1950)3:1<32::AID-CNCR2820030106>3.0.CO;2-3
52. Zhang Z, Bast RC, Yu Y, Li J, Sokoll LJ, Rai AJ, Rosenzweig JM, Cameron B, Wang YY, Meng XY, Berchuck A, Van Haaften-Day C, Hacker NF, de Bruijn HW, van der Zee AG, Jacobs IJ, Fung ET, Chan DW. 2004. Three biomarkers identified from serum proteomic analysis for the detection of early stage ovarian cancer. Cancer Research 64:5882-5890. DOI:https://doi.org/10.1158/0008-5472.CAN-04-0746
53. Zhang WC, Chin TM, Yang H, Nga ME, Lunny DP, Lim EK, Sun LL, Pang YH, Leow YN, Malusay SR, Lim PX, Lee JZ, Tan BJ, Shyh-Chang N, Lim EH, Lim WT, Tan DS, Tan EH, Tai BC, Soo RA, et al. 2016. Tumour-initiating cell-specific miR-1246 and miR-1290 expression converge to promote non-small cell lung cancer progression. Nature Communications 7:11702. DOI:https://doi.org/10.1038/ncomms11702
54. Zheng H, Zhang L, Zhao Y, Yang D, Song F, Wen Y, Hao Q, Hu Z, Zhang W, Chen K. 2013. Plasma miRNAs as diagnostic and prognostic biomarkers for ovarian cancer. PLoS One 8:e77853. DOI:https://doi.org/10.1371/journal.pone.0077853
55. Zhu CS, Pinsky PF, Cramer DW, Ransohoff DF, Hartge P, Pfeiffer RM, Urban N, Mor G, Bast RC, Moore LE, Lokshin AE, McIntosh MW, Skates SJ, Vitonis A, Zhang Z, Ward DC, Symanowski JT, Lomakin A, Fung ET, Sluss PM, et al. 2011. A framework for evaluating biomarkers for early detection: validation of biomarker panels for ovarian cancer. Cancer Prevention Research 4:375-383. DOI:https://doi.org/10.1158/1940-6207.CAPR-10-0193
56. Zuberi M, Mir R, Das J, Ahmad I, Javid J, Yadav P, Masroor M, Ahmad S, Ray PC, Saxena A. 2015. Expression of serum miR-200a, miR-200b, and miR-200c as candidate biomarkers in epithelial ovarian cancer and their association with clinicopathological features. Clinical and Translational Oncology 17:779-787. DOI:https://doi.org/10.1007/s12094-015-1303-1